Long-Acting Octreotide LAR Compared with Lanreotide SR in the Treatment of Acromegaly
- 1 October 2000
- journal article
- Published by Springer Nature in Pituitary
- Vol. 3 (2) , 61-65
Abstract
The use of somatostatin analogues for the treatment of acromegaly is now well established. Recently long-acting preparations of octreotide and lanreotide have been introduced. In this study we have...Keywords
This publication has 27 references indexed in Scilit:
- The Therapeutic Value of Somatostatin and Its AnaloguesPituitary, 1999
- Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretionClinical Endocrinology, 1999
- Current Treatment Guidelines for Acromegaly1The Journal of Clinical Endocrinology & Metabolism, 1998
- Sandostatin LAR in Acromegalic Patients: Long Term TreatmentThe Journal of Clinical Endocrinology & Metabolism, 1997
- OctreotideNew England Journal of Medicine, 1996
- Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly.The Journal of Clinical Endocrinology & Metabolism, 1995
- Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotideEuropean Journal of Endocrinology, 1994
- A long-term dose-response study of somatostatin analogue (SMS 201–995, octreotide) in resistant acromegalyClinical Endocrinology, 1991
- Treatment of Acromegaly with the Long-Acting Somatostatin Analog SMS 201-995*The Journal of Clinical Endocrinology & Metabolism, 1988
- Medical Treatment of Acromegaly with SMS 201-995, a Somatostatin Analog: A Comparison with Bromocriptine*The Journal of Clinical Endocrinology & Metabolism, 1987